Genome-wide association study of CSF biomarkers AÎ² _{181p} in the ADNI cohort

Neurology

76, 69-79

DOI: 10.1212/wnl.0b013e318204a397

Citation Report

#	Article	IF	Citations
1	Intersectional innovation in biomarker development for patient-centric medicine. Personalized Medicine, 2011, 8, 469-481.	1.5	1
2	The role of genetics for biomarker development in neurodegeneration. Progress in Neurobiology, 2011, 95, 501-504.	5.7	24
3	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	2.6	41
4	Genetic Risk Factors: Their Function and Comorbidities in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-2.	2.0	1
5	Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. Neuropsychiatric Disease and Treatment, 2011, 7, 495.	2.2	30
6	Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-22.	2.0	33
7	Alzheimer's disease genetics: lessons to improve disease modelling. Biochemical Society Transactions, 2011, 39, 910-916.	3.4	37
8	Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimerâ€™s Disease Cerebrospinal Fluid Markers. Dementia and Geriatric Cognitive Disorders, 2011, 32, 164-170.	1.5	39
9	The "Alzheimer's disease signature": potential perspectives for novel biomarkers. Immunity and Ageing, 2011, 8, 7.	4.2	17
10	Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk. Molecular Neurodegeneration, 2011, 6, 62.	10.8	11
11	Neurological imaging: statistics behind the pictures. Imaging in Medicine, 2011, 3, 423-432.	0.0	4
12	Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild cognitive impairment. Translational Psychiatry, 2011, 1, e54-e54.	4.8	48
13	Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology, 2012, 37, 261-277.	5.4	43
14	Biochemical Studies of Poly-T Variants in the Alzheimer's Disease Associated TOMM40 Gene. Journal of Alzheimer's Disease, 2012, 31, 527-536.	2.6	17
15	Maternal Family History is Associated with Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2012, 31, 659-668.	2.6	53
16	Value of Neuropsychological Testing, Imaging, and CSF Biomarkers for the Differential Diagnosis and Prognosis of Clinically Ambiguous Dementia. Journal of Alzheimer's Disease, 2012, 28, 323-336.	2.6	17
17	HIV and Aging. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S1-S18.	2.1	474
18	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2012, 8, S1-68.	0.8	432

#	Article	IF	Citations
19	Development of biomarkers to chart all Alzheimer's disease stages: TheÂroyal road to cutting the therapeutic Gordian Knot. Alzheimer's and Dementia, 2012, 8, 312-336.	0.8	112
20	Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. Journal of Human Genetics, 2012, 57, 18-25.	2.3	83
21	Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1486.e9-1486.e15.	3.1	25
22	Structural and functional neural correlates of visuospatial information processing in normal aging and amnestic mild cognitive impairment. Neurobiology of Aging, 2012, 33, 2782-2797.	3.1	35
23	Relationship between genetic risk factors and markers for Alzheimerâ€™s disease pathology. Biomarkers in Medicine, 2012, 6, 477-495.	1.4	25
24	ABC Transporters and the Alzheimerâ€™s Disease Enigma. Frontiers in Psychiatry, 2012, 3, 54.	2.6	80
25	Promising Genetic Biomarkers of Preclinical Alzheimer's Disease: The Influence ofAPOEandTOMM40on Brain Integrity. International Journal of Alzheimer's Disease, 2012, 2012, 1-15.	2.0	25
26	A REVIEW OF BIOCHEMICAL MARKERS FOR EARLY DIAGNOSIS OF ALZHEIMERÃ¢Â€Â™S DISEASE. American Journal of Neuroscience, 2012, 3, 54-62.	0.4	2
27	The release of S-100B and NSE in severe traumatic head injury is associated with APOE Îµ4. Acta Neurochirurgica, 2012, 154, 675-680.	1.7	18
28	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimerâ€™s Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	2.1	47
29	Other Genes Implicated in Alzheimerâ€™s Disease. , 2013, , 209-230.		0
30	Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 2013, 126, 671-682.	7.7	76
31	Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 553-560.	3.2	47
32	A Quantum Dot Probe Conjugated with AÎ² Antibody for Molecular Imaging of Alzheimerâ€™s Disease in a Mouse Model. Cellular and Molecular Neurobiology, 2013, 33, 759-765.	3.3	29
34	Epigenetic signature and enhancer activity of the human APOE gene. Human Molecular Genetics, 2013, 22, 5036-5047.	2.9	59
35	Alzheimer's disease risk genes and the age-at-onset phenotype. Neurobiology of Aging, 2013, 34, 2696.e1-2696.e5.	3.1	27
36	The National Institute on Aging-Alzheimerâ€™s Association research criteria for mild cognitive impairment due to Alzheimerâ€™s disease: predicting the outcome. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 325-333.	3.2	27
37	Genetic insights in Alzheimer's disease. Lancet Neurology, The, 2013, 12, 92-104.	10.2	310

#	Article	IF	Citations
38	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.8	535
39	TOMM40 intron 6 polyâ€T length, age at onset, and neuropathology of AD in individuals with APOE É›3/É›3. Alzheimer's and Dementia, 2013, 9, 554-561.	0.8	27
40	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimerâ€™s Disease. Neuron, 2013, 78, 256-268.	8.1	344
41	Association of TOMM40 Polymorphisms with Late-Onset Alzheimerâ€™s Disease in a Northern Han Chinese Population. NeuroMolecular Medicine, 2013, 15, 279-287.	3.4	29
42	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesisâ€"but what lies beyond?. Biochemical Pharmacology, 2013, 85, 289-305.	4.4	181
43	Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry, 2013, 18, 781-787.	7.9	81
44	Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection. Annual Review of Clinical Psychology, 2013, 9, 621-648.	12.3	110
45	Plasma Proteomics for the Identification of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 337-342.	1.3	47
46	Influence of TSPO Genotype on ¹¹C-PBR28 Standardized Uptake Values. Journal of Nuclear Medicine, 2013, 54, 1320-1322.	5.0	56
47	Insights into the Genetic Architecture of Early Stage Age-Related Macular Degeneration: A Genome-Wide Association Study Meta-Analysis. PLoS ONE, 2013, 8, e53830.	2.5	108
48	Association between NME8 Locus Polymorphism and Cognitive Decline, Cerebrospinal Fluid and Neuroimaging Biomarkers in Alzheimer's Disease. PLoS ONE, 2014, 9, e114777.	2.5	37
49	Genetic variation modifies risk for neurodegeneration based on biomarker status. Frontiers in Aging Neuroscience, 2014, 6, 183.	3.4	18
50	The Pathogenic Component of the APOE-TOMM40 Region in Alzheimerâ€™s disease: Its Implications in Metabolomics and Pharmacogenomics. Metabolomics: Open Access, 2014, 04, .	0.1	0
51	Journal of Parkinsonâ€™s disease & Alzheimerâ€™s disease. Journal of Parkinson's Disease and Alzheimer's Disease, 2014, 1, .	0.8	56
52	SUCLG2 identified as both a determinator of CSF AÎ²1â€"42 levels and an attenuator of cognitive decline in Alzheimer's disease. Human Molecular Genetics, 2014, 23, 6644-6658.	2.9	45
53	Replicative association analysis of genetic markers of cognitive traits with Alzheimerâ€™s disease in the Russian population. Molecular Biology, 2014, 48, 835-844.	1.3	13
54	Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation. PLoS Genetics, 2014, 10, e1004758.	3.5	109
55	Genetic modification of the relationship between phosphorylated tau and neurodegeneration. Alzheimer's and Dementia, 2014, 10, 637.	0.8	21

#	Article	IF	Citations
56	Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S425-S429.e1.	0.8	35
57	The role of synaptic activity in the regulation of amyloid beta levels in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1217-1232.	3.1	36
58	Genetic Discoveries in AD Using CSF Amyloid and Tau. Current Genetic Medicine Reports, 2014, 2, 23-29.	1.9	10
59	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	2.1	161
60	Alzheimerâ€™s and ABC transporters â€" new opportunities for diagnostics and treatment. Neurobiology of Disease, 2014, 72, 54-60.	4.4	66
61	A genome-wide association meta-analysis of plasma AÎ² peptides concentrations in the elderly. Molecular Psychiatry, 2014, 19, 1326-1335.	7.9	36
62	The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. European Neuropsychopharmacology, 2014, 24, 1492-1499.	0.7	24
63	The association between TOMM40 gene polymorphism and spontaneous brain activity in amnestic mild cognitive impairment. Journal of Neurology, 2014, 261, 1499-1507.	3.6	21
64	Alzheimerâ€™s Disease Genetics: From the Bench to the Clinic. Neuron, 2014, 83, 11-26.	8.1	396
65	Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population. Neurobiology of Aging, 2014, 35, 936.e5-936.e12.	3.1	47
66	Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 684-689.	0.8	54
67	Treatment of Alzheimerâ€™s Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. Journal of Alzheimer's Disease, 2015, 47, 149-156.	2.6	49
68	Epistasis analysis links immune cascades and cerebral amyloidosis. Journal of Neuroinflammation, 2015, 12, 227.	7.2	10
69	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. Journal of Alzheimer's Disease, 2015, 45, 1197-1206.	2.6	33
70	Genetic Interactions Explain Variance in Cingulate Amyloid Burden: An AV-45 PET Genome-Wide Association and Interaction Study in the ADNI Cohort. BioMed Research International, 2015, 2015, 1-11.	1.9	24
71	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: AÂreview of papers published since its inception. Alzheimer's and Dementia, 2015, 11, e1-120.	0.8	261
72	Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. Neurobiology of Aging, 2015, 36, 2907.e1-2907.e10.	3.1	25
73	Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. Future Neurology, 2015, 10, 229-252.	0.5	25

#	Article	IF	Citations
74	Alzheimer Disease. , 2015, , 321-338.		9
75	The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimerâ€™s Disease: Results of a Randomized Trial. Journal of Alzheimer's Disease, 2016, 52, 1299-1310.	2.6	49
76	ABCA7 Genotypes Confer Alzheimerâ€™s Disease Risk by Modulating Amyloid-Î² Pathology. Journal of Alzheimer's Disease, 2016, 52, 693-703.	2.6	16
77	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Journal of Parkinson's Disease, 2016, 6, 99-108.	2.8	6
78	Redox Based-Peripheral Biomarkers in Alzheimerâ€™s Disease: Challenges, Limits and Prospects. Oxidative Stress in Applied Basic Research and Clinical Practice, 2016, , 377-397.	0.4	1
79	A human carboxypeptidase E/NF-Î±1 gene mutation in an Alzheimerâ€™s disease patient leads to dementia and depression in mice. Translational Psychiatry, 2016, 6, e973-e973.	4.8	22
80	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 51.	6.2	19
81	Prediction of later clinical course by a specific glucose metabolic pattern in non-demented patients with probable REM sleep behavior disorder admitted to a memory clinic: A case study. Psychiatry Research - Neuroimaging, 2016, 248, 151-158.	1.8	12
82	Genetic loci associated with ideal cardiovascular health: A meta-analysis of genome-wide association studies. American Heart Journal, 2016, 175, 112-120.	2.7	25
83	Alzheimerâ€™s Disease Cerebrospinal Fluid (CSF) Biomarkers. , 2016, , 139-180.		4
84	The TOMM40 gene rs2075650 polymorphism contributes to Alzheimerâ€™s disease in Caucasian, and Asian populations. Neuroscience Letters, 2016, 628, 142-146.	2.1	31
85	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimerâ€™s disease. BMC Medical Genomics, 2016, 9, 30.	1.5	20
86	Association Analysis of Polymorphisms in TOMM40, CR1, PVRL2, SORL1, PICALM, and 14q32.13 Regions in Colombian Alzheimer Disease Patients. Alzheimer Disease and Associated Disorders, 2016, 30, 305-309.	1.3	15
87	Combined Genome-Wide CSF AÎ²-42â€™s Associations and Simple Network Properties Highlight New Risk Factors for Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2016, 58, 120-128.	2.3	11
88	An Overview of Genome-Wide Association Studies in Alzheimerâ€™s Disease. Neuroscience Bulletin, 2016, 32, 183-190.	2.9	72
89	Dissecting Complex and Multifactorial Nature of Alzheimerâ€™s Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. Molecular Neurobiology, 2016, 53, 4833-4864.	4.0	52
90	Mapping CSF biomarker profiles onto NIAâ€“AA guidelines for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 587-597.	3.2	14
91	Genome-wide association study identifies MAPT locus influencing human plasma tau levels. Neurology, 2017, 88, 669-676.	1.1	33

#	Article	IF	Citations
92	Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathologica, 2017, 133, 785-807.	7.7	67
93	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	7.7	199
94	Hippocampal thinning linked to longer TOMM40 polyâ€T variant lengths in the absence of the APOE Îµ4 variant. Alzheimer's and Dementia, 2017, 13, 739-748.	0.8	25
95	State of Play in Alzheimerâ€™s Disease Genetics. Journal of Alzheimer's Disease, 2017, 58, 631-659.	2.6	34
96	Transcriptome-wide piRNA profiling in human brains of Alzheimer's disease. Neurobiology of Aging, 2017, 57, 170-177.	3.1	71
97	Biomarkers and Functional Decline inÂProdromal Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 69-78.	2.6	9
98	RGS2 and SIRT1 Link Renin Angiotensin Aldosterone System to Alzheimerâ€™s Disease. , 2017, , 239-251.		3
99	Genomic variants, genes, and pathways of Alzheimer's disease: An overview. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 5-26.	1.7	147
100	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	3.1	70
101	A sequential tree-based classifier for personalized biomarker testing of Alzheimer's disease risk. IISE Transactions on Healthcare Systems Engineering, 2017, 7, 248-260.	1.7	6
102	Differences in the frequency of Alzheimer's diseaseâ€associated genomic variations in populations of different races. Geriatrics and Gerontology International, 2017, 17, 2184-2193.	1.5	10
103	Genome-wide significant, replicated and functional risk variants for Alzheimerâ€™s disease. Journal of Neural Transmission, 2017, 124, 1455-1471.	2.8	10
104	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimerâ€™s disease. BMC Medical Genomics, 2017, 10, 29.	1.5	28
105	Genome-wide network-based pathway analysis of CSF t-tau/AÎ²1-42 ratio in the ADNI cohort. BMC Genomics, 2017, 18, 421.	2.8	13
106	Analysis of the joint effect of SNPs to identify independent loci and allelic heterogeneity in schizophrenia GWAS data. Translational Psychiatry, 2017, 7, 1289.	4.8	4
107	Whole exome sequence-based association analyses of plasma amyloid-Î² in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study. PLoS ONE, 2017, 12, e0180046.	2.5	18
108	Alterations in cholesterol metabolismâ€"related genes in sporadic Alzheimer's disease. Neurobiology of Aging, 2018, 66, 180.e1-180.e9.	3.1	39
109	Genomeâ€wide association study of Alzheimer's disease endophenotypes at prediagnosis stages. Alzheimer's and Dementia, 2018, 14, 623-633.	0.8	64

#	Article	IF	Citations
110	Fluid biomarker agreement and interrelation in dementia due to Alzheimerâ€™s disease. Journal of Neural Transmission, 2018, 125, 193-201.	2.8	5
111	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	2.6	12
112	Association of MAPT haplotypeâ€tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort. Brain and Behavior, 2018, 8, e01128.	2.2	20
113	Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity. BMC Medical Genetics, 2018, 19, 75.	2.1	21
114	Development of Multiplex Genotyping Method of Polymorphic Markers of Genes Associated with Cognitive Abilities. Russian Journal of Genetics, 2018, 54, 740-745.	0.6	1
116	Commentary: Endophenotypes as Disease Modifiers: Decoding the Biology of Alzheimerâ€™s by Genome-wide Association Studies. CNS and Neurological Disorders - Drug Targets, 2018, 17, 6-8.	1.4	4
117	Genome-wide association study identifies two loci influencing plasma neurofilament light levels. BMC Medical Genomics, 2018, 11, 47.	1.5	15
118	Data integration for functional annotation of regulatory single nucleotide polymorphisms associated with Alzheimer's disease susceptibility. Gene, 2018, 672, 115-125.	2.2	7
119	A Genome-Wide Association Study of Î±-Synuclein Levels in Cerebrospinal Fluid. Neurotoxicity Research, 2019, 35, 41-48.	2.7	7
120	A decade in psychiatric GWAS research. Molecular Psychiatry, 2019, 24, 378-389.	7.9	78
121	Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nature Communications, 2019, 10, 3160.	12.8	42
122	Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update. Frontiers in Pharmacology, 2019, 10, 902.	3.5	173
123	Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiology of Aging, 2019, 84, 241.e13-241.e20.	3.1	35
124	Sirtuins in Alzheimerâ€™s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics. International Journal of Molecular Sciences, 2019, 20, 1249.	4.1	64
125	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	3.5	46
126	New APOE-related therapeutic options for Alzheimerâ€™s disease. AIP Conference Proceedings, 2019, , .	0.4	4
127	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of Aging, 2019, 74, 182-190.	3.1	45
128	The FAM171A2 gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases. Science Advances, 2020, 6, .	10.3	9

#	Article	IF	Citations
129	Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale. Cells, 2020, 9, 2642.	4.1	32
130	Association of Uncommon, Noncoding Variants in the APOE Region With Risk of Alzheimer Disease in Adults of European Ancestry. JAMA Network Open, 2020, 3, e2017666.	5.9	13
131	MicroRNA-298 reduces levels of human amyloid-Î² precursor protein (APP), Î²-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties. Molecular Psychiatry, 2021, 26, 5636-5657.	7.9	61
132	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology, 2021, 96, e1358-e1368.	1.1	11
133	Genetic Variability in Molecular Pathways Implicated in Alzheimer's Disease: A Comprehensive Review. Frontiers in Aging Neuroscience, 2021, 13, 646901.	3.4	16
134	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. Neurobiology of Disease, 2021, 151, 105247.	4.4	3
135	Insomnia Moderates the Relationship Between Amyloid-Î² and Cognitive Decline in Late-Life Adults without Dementia. Journal of Alzheimer's Disease, 2021, 81, 1701-1710.	2.6	4
136	Use of Deep-Learning Genomics to Discriminate Healthy Individuals from Those with Alzheimerâ€™s Disease or Mild Cognitive Impairment. Behavioural Neurology, 2021, 2021, 1-15.	2.1	11
137	Post-translational modifications: Regulators of neurodegenerative proteinopathies. Ageing Research Reviews, 2021, 68, 101336.	10.9	45
138	Group penalized quantile regression. Statistical Methods and Applications, 2022, 31, 495-529.	1.2	1
139	Association and Interaction of TOMM40 and PVRL2 with Plasma Amyloid-Î’ and Alzheimer's Disease Among Chinese Older Adults: A Population-Based Study. SSRN Electronic Journal, 0, , .	0.4	0
140	Genetic Loci Associated with Alzheimerâ€™s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. PLoS ONE, 2013, 8, e59676.	2.5	61
141	Prevalence of Alzheimerâ€™s Pathologic Endophenotypes in Asymptomatic and Mildly Impaired First-Degree Relatives. PLoS ONE, 2013, 8, e60747.	2.5	18
142	Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid AÎ²1-42 Level. PLoS ONE, 2015, 10, e0134000.	2.5	39
143	Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. Aging, 2019, 11, 4521-4535.	3.1	8
144	Genome-wide association study identifies SIAH3 locus influencing the rate of ventricular enlargement in non-demented elders. Aging, 2019, 11, 9862-9874.	3.1	4
145	Association of Alzheimerâ€™s disease risk variants on the PICALM gene with PICALM expression, core biomarkers, and feature neurodegeneration. Aging, 2020, 12, 21202-21219.	3.1	7
146	Low Plasma Leptin in Cognitively Impaired ADNI Subjects: Gender Differences and Diagnostic and Therapeutic Potential. Current Alzheimer Research, 2014, 11, 165-174.	1.4	54

#	Article	IF	Citations
147	Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE Îµ 4 Non-Carriers of Alzheimerâ€™s Disease. Current Alzheimer Research, 2015, 12, 218-227.	1.4	13
148	APOE-TOMM40 in the Pharmacogenomics of Dementia. Journal of Pharmacogenomics & Pharmacoproteomics, 2013, 05, .	0.2	6
149	Biomarkers for the early diagnosis of Alzheimerâ€™s disease: The challenge of XXI century. Advances in Alzheimer's Disease, 2013, 02, 13-30.	0.9	10
150	Identification of altered exosomal microRNAs and mRNAs in Alzheimer's disease. Ageing Research Reviews, 2022, 73, 101497.	10.9	38
152	Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. Frontiers in Neuroscience, 2012, , 87-102.	0.0	0
154	Genome-wide association study identifies CBFA2T3 affecting the rate of CSF AÎ²42 decline in non-demented elders. Aging, 2019, 11, 5433-5444.	3.1	5
155	A geneâ€“environment interplay between omegaâ€3 supplementation and APOE Îµ4 provides insights for Alzheimerâ€™s disease precise prevention amongst highâ€geneticâ€risk population. European Journal of Neurology, 2022, 29, 422-431.	3.3	6
156	TOMM40 rs2075650 polymorphism shows no association with neovascular age-related macular degeneration or polypoidal choroidal vasculopathy in a Chinese population. Molecular Vision, 2013, 19, 2050-7.	1.1	4
158	Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. AMIA Summits on Translational Science Proceedings, 2018, 2017, 124-131.	0.4	6
159	Genome-Wide association study of quantitative biomarkers identifies a novel locus for alzheimerâ€™s disease at 12p12.1. BMC Genomics, 2022, 23, 85.	2.8	7
160	Identifying differential regulatory control of APOE É›4 on African versus European haplotypes as potential therapeutic targets. Alzheimer's and Dementia, 2022, 18, 1930-1942.	0.8	12
161	Association and interaction of TOMM40 and PVRL2 with plasma amyloid-Î² and Alzheimer's disease among Chinese older adults: a population-based study. Neurobiology of Aging, 2022, 113, 143-151.	3.1	12
162	Dissection of the polygenic architecture of neuronal AÎ² production using a large sample of individual iPSC lines derived from Alzheimerâ€™s disease patients. Nature Aging, 2022, 2, 125-139.	11.6	7
163	Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels. Journal of Human Genetics, 2022, 67, 459-463.	2.3	4
164	Use of deep learning genomics to discriminate Alzheimer's disease and healthy controls. , 2021, 2021, 5788-5791.		1
166	The Big Picture of Neurodegeneration: A Meta Study to Extract the Essential Evidence on Neurodegenerative Diseases in a Network-Based Approach. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
167	Alzheimer's Disease Blood Biomarkers Associated With Neuroinflammation as Therapeutic Targets for Early Personalized Intervention. Frontiers in Digital Health, 0, 4, .	2.8	1
168	Association between theLRP1BandAPOEloci and the development of Parkinsonâ€™s disease dementia. Brain, 2023, 146, 1873-1887.	7.6	12

#	Article	IF	Citations
169	Wholeâ€exome rareâ€variant analysis of Alzheimer's disease and related biomarker traits. Alzheimer's and Dementia, 0, , .	0.8	1
171	Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-218.	1.8	1
172	Genome-wide Survival Study Identifies PARL as a Novel Locus for Clinical Progression and Neurodegeneration in Alzheimerâ€™s Disease. Biological Psychiatry, 2023, 94, 732-742.	1.3	1
174	The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. American Journal of Clinical Nutrition, 2023, 117, 1096-1109.	4.7	13
175	A global view of the genetic basis of Alzheimer disease. Nature Reviews Neurology, 2023, 19, 261-277.	10.1	19
177	Hippocampal delivery of neurotrophic factor-Î±1/carboxypeptidase E gene prevents neurodegeneration, amyloidosis, memory loss in Alzheimerâ€™s Disease male mice. Molecular Psychiatry, 2023, 28, 3332-3342.	7.9	1
178	Alzheimerâ€™s disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation, 2023, 20, .	7.2	4
179	The Association of Selected GWAS Reported AD Risk Loci with CSF Biomarker Levels and Cognitive Decline in Slovenian Patients. International Journal of Molecular Sciences, 2023, 24, 12966.	4.1	0
180	Genomeâ€Wide Metaâ€Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts. Movement Disorders, 2023, 38, 1697-1705.	3.9	2
183	X chromosome-wide association study of quantitative biomarkers from the Alzheimerâ€™s Disease Neuroimaging Initiative study. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
184	Uncovering the Localization and Function of a Novel Read-Through Transcript â€˜TOMM40-APOEâ€™. Cells, 2024, 13, 69.	4.1	0
185	Knowledge domains and emerging trends of Genome-wide association studies in Alzheimerâ€™s disease: A bibliometric analysis and visualization study from 2002 to 2022. PLoS ONE, 2024, 19, e0295008.	2.5	0